Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

For patients with diabetes, exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with an increased ...

The first reason is because the mechanism of action [MOA] of using a GLP-1 Receptor ... short amount of 12-weeks already proved that its GLP-1 RA MET-097i already attained a mean placebo adjusted ...

Compounded vs non-compounded GLP-1 RA drug products are associated with an increased risk for adverse events such as nausea and diarrhea.

Combination therapy with GLP-1 RA and thiazolidinedione significantly reduces all-cause mortality and cardiovascular mortality in type 2 diabetes patients. The study found an increased risk of ...

Greatest increase in SGLT2 inhibitor use seen in subgroups with cardiovascular disease; greatest increase in GLP-1 RA for those with obesity. HealthDay News — From 2010 to 2023, there was an ...

The researchers found that the incidence of VTE was 11.0 versus 12.9 events per 1,000 patient-years in the GLP-1 RA and DPP-4 inhibitor cohorts, respectively, with an 18 percent lower risk for VTE ...

The 5-year unadjusted cumulative incidence of death-censored graft loss from a cohort matched on survival time before GLP-1 RA initiation was 6.0% for GLP-1 RA users and 10.7% for nonusers.

WASHINGTON — Glucagon-like peptide 1 receptor agonist (GLP-1 RA) medications appear beneficial for people with systemic lupus erythematosus (SLE) and lupus nephritis, two new studies suggest.

Twelve GLP-1 RA medications were studied, 3 that are FDA-approved (liraglutide, semaglutide, and tirzepatide) and 9 that are not yet approved for weight management. Treatment periods lasted from ...

A nationwide study using the French National Health Data System (SNDS) (2013-2021) evaluated the short-term association between GLP-1 RA and suicidal behaviors. The SNDS contains anonymized ...

The researchers found that the incidence of VTE was 11.0 versus 12.9 events per 1,000 patient-years in the GLP-1 RA and DPP-4 inhibitor cohorts, respectively, with an 18% lower risk for VTE for ...